A Multicentered, Randomized, Open-Label, Pragmatic Use Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation
Phase of Trial: Phase IV
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Vernakalant (Primary) ; Amiodarone
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 04 Aug 2017 Status changed from completed to discontinued.
- 20 Feb 2013 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 17 Oct 2012 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.